Search details
1.
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Mol Cancer Ther
; 21(2): 322-335, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34789563
2.
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
Cancer Res
; 82(1): 130-141, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34548332
3.
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.
J Clin Invest
; 131(2)2021 01 19.
Article
in English
| MEDLINE | ID: mdl-33151910
4.
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
Clin Cancer Res
; 27(1): 276-287, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-33239433
5.
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Cancer Cell
; 37(1): 104-122.e12, 2020 01 13.
Article
in English
| MEDLINE | ID: mdl-31935369
6.
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Cancer Discov
; 9(1): 34-45, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30297358
7.
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Clin Cancer Res
; 25(20): 6127-6140, 2019 10 15.
Article
in English
| MEDLINE | ID: mdl-31409614
8.
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Cancer Immunol Res
; 7(9): 1457-1471, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31331945
9.
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.
Cancer Immunol Res
; 6(12): 1511-1523, 2018 12.
Article
in English
| MEDLINE | ID: mdl-30242021
10.
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Elife
; 72018 11 13.
Article
in English
| MEDLINE | ID: mdl-30422115
11.
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
Cancer Cell
; 34(3): 439-452.e6, 2018 09 10.
Article
in English
| MEDLINE | ID: mdl-30205046
12.
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
Clin Cancer Res
; 24(23): 5963-5976, 2018 12 01.
Article
in English
| MEDLINE | ID: mdl-30072474
13.
Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.
J Clin Invest
; 127(12): 4554-4568, 2017 12 01.
Article
in English
| MEDLINE | ID: mdl-29130934
14.
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Clin Cancer Res
; 23(5): 1263-1273, 2017 Mar 01.
Article
in English
| MEDLINE | ID: mdl-27573169
15.
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.
Leukemia
; 29(7): 1555-1563, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25703587
16.
Evaluating TBK1 as a therapeutic target in cancers with activated IRF3.
Mol Cancer Res
; 12(7): 1055-66, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24752990
Results
1 -
16
de 16
1
Next >
>>